Table 3. Analysis of inflammatory markers in peripheral blood, ASDAS, BASDAI, SF-36, EQ-5D, EQ-5D VAS and HADS during the 8-week intervention period.
| Intervention group | Intra-group p value# |
Control group | Intra-group p value# |
|||||
|---|---|---|---|---|---|---|---|---|
| Baseline (n = 21) | 4w (n = 21) |
8w (n = 19) |
Baseline (n = 11) | 4w (n = 11) |
8w (n = 11) |
|||
| hs-CRP (mg/l) | 10.2 (6.5–17.1) |
8.9 (3.5–13.1) |
6 (3.9–15.6) |
.103 | 8.7 (5.2–17.2) |
11 (8.4–20.2) |
13.2 (7.9–20.1) |
.286 |
| ESR (mm/hr) | 16 (9–26.5) |
10 (6.5–31.5) |
9 (5–23) |
.040* | 14 (8.3–27.3) |
12 (8–34) |
16 (5–37) |
.406 |
| Calprotectin (pg/ml) | 2295 (1648–4923) | 2245 (1273–3245) | 2165 (953–3734) | .064 | 2115 (1300–2571) | 2086 (1221–3527) |
2279 (1770–4989) |
.182 |
| ASDAS-CRP | 3.1 (2.5–3.6) |
2.5 (1.9–3.2) |
2.3 (1.7–3.2) |
.044* | 2.9 (2.3–3.6) |
3.4 (3–3.6) |
3.1 (2.7–3.6) |
.213 |
| BASDAI | 4.5 (3–5.9) |
3.3 (2.1–5.8) |
2.6 (1.4–3.5) |
.012* | 3.2 (2.8–5.5) |
5.5 (3–6.2) |
4.3 (2.5–5.7) |
.755 |
| SF-36 PCS | 44.8 (36.0–48.8) | 44.6 (39.9–47.4) | 49.3 (40.7–54.7) | .004* | 41.8 (34.1–49.1) | 42.1 (35.9–46.1) |
42.8 (33.5–48.0) |
.859 |
| SF-36 MCS | 45.5 (39.9–53.5) |
50.4 (44.3–54.6) |
53.5 (46.8–56.7) |
.004* | 42.0 (38.1–50.4) |
45.0 (37.2–53.9) |
42.6 (40.0–52.5) |
.859 |
| EQ-5D | .81 (.65-.84) |
.81 (.67-.92) |
0.84 (.81–1.00) |
.102 | .81 (.69-.84) |
.81 (.25-.81) |
.81 (.65-.84) |
.933 |
| EQ-5D VAS | 66.5 (59.3–74.0) |
70.0 (55.5–76.0) |
75.5 (70.0–87.0) |
.090 | 67.5 (48.3–76.3) |
60.0 (45.0–72.5) |
66.5 (62.0–75.5) |
.674 |
| HADS-Anxiety | 5.0 (2.5–7.5) |
4.0 (2.5–6.0) |
4.0 (.5–6.0) |
.369 | 5.0 (3.0–7.0) |
5.0 (4.0–6.0) |
3.0 (1.0–5.0) |
.138 |
| HADS-Depression | 3(1–6) | 3(1–6) | 2(1–6) | .508 | 3(2–6) | 4(1–5) | 1(1–4) | .137 |
Values are presented as median (interquartile range).
*: P < .05
#Wilcoxon signed rank test